This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Salgia, Ravi
| Item Type | Name |
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
|
|
Academic Article
|
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
|
Academic Article
|
EphB4 as a therapeutic target in mesothelioma.
|
|
Academic Article
|
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.
|
|
Academic Article
|
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
|
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
|
Academic Article
|
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
|
|
Academic Article
|
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
|
|
Academic Article
|
Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
|
|
Academic Article
|
Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
|
|
Academic Article
|
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
|
- Antibodies Monoclonal Humanized